Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Mymetics
Mymetics
Activities:
Manufacturing
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Optimising RNA production for faster and cheaper pharmaceutical manufacturing
RNA production can be a lengthy and complex process, but the Ntensify platform could change this by diminishing development times, decreasing production costs and allowing the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool
The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Mymetics-led consortium awarded €8.4m to develop thermo stable and cold-chain independent vaccines
Virosome vaccine technology and HIV vaccine candidate to be used to develop scalable manufacturing process within 3.5 years
Research & Development
Mymetics to advance development of virosome-based malaria vaccine candidate
In partnership with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the NIH
Research & Development
Mymetics’ HIV vaccine candidate to begin study at Texas Biomedical Research Institute
Follows a successfully completed smaller study at the Institute of Laboratory Animal Science (ILAS)
Research & Development
Astellas forms partnership with ClearPath to build vaccine portfolio
In-license vaccine technology for Respiratory Syncytial Virus (RSV) from Mymetics
Research & Development
Mymetics announces change of directors and management
Will explore a number of strategic opportunities for its HIV, RSV and other vaccine candidates
Pharmaceutical
Mymetics makes two appointments
New president and ceo and chairman
Subscribe now